These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
24. Significance of Receptor Mobility in Multivalent Binding on Lipid Membranes. Morzy D; Bastings M Angew Chem Int Ed Engl; 2022 Mar; 61(13):e202114167. PubMed ID: 34982497 [TBL] [Abstract][Full Text] [Related]
25. Nanoscale binding site localization by molecular distance estimation on native cell surfaces using topological image averaging. Kumra Ahnlide V; Kumra Ahnlide J; Wrighton S; Beech JP; Nordenfelt P Elife; 2022 Feb; 11():. PubMed ID: 35200140 [TBL] [Abstract][Full Text] [Related]
27. Spotlight on liver macrophages for halting liver disease progression and injury. Khurana A; Navik U; Allawadhi P; Yadav P; Weiskirchen R Expert Opin Ther Targets; 2022 Aug; 26(8):707-719. PubMed ID: 36202756 [TBL] [Abstract][Full Text] [Related]
28. Macrophages and CSF-1: implications for development and beyond. Jones CV; Ricardo SD Organogenesis; 2013 Oct; 9(4):249-60. PubMed ID: 23974218 [TBL] [Abstract][Full Text] [Related]
29. Advancements in Macrophage-Targeted Drug Delivery for Effective Disease Management. Liu H; Lv H; Duan X; Du Y; Tang Y; Xu W Int J Nanomedicine; 2023; 18():6915-6940. PubMed ID: 38026516 [TBL] [Abstract][Full Text] [Related]
30. Macrophage phenotypes in tissue repair and the foreign body response: Implications for biomaterial-based regenerative medicine strategies. Martin KE; García AJ Acta Biomater; 2021 Oct; 133():4-16. PubMed ID: 33775905 [TBL] [Abstract][Full Text] [Related]
31. Macrophage-related therapeutic strategies: Regulation of phenotypic switching and construction of drug delivery systems. Wang X; Li Y; Pu X; Liu G; Qin H; Wan W; Wang Y; Zhu Y; Yang J Pharmacol Res; 2024 Jan; 199():107022. PubMed ID: 38043691 [TBL] [Abstract][Full Text] [Related]
35. Optimal multivalent targeting of membranes with many distinct receptors. Curk T; Dobnikar J; Frenkel D Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7210-7215. PubMed ID: 28652338 [TBL] [Abstract][Full Text] [Related]
36. Developmental programming of macrophages by early life adversity. Magalhaes MS; Potter HG; Ahlback A; Gentek R Int Rev Cell Mol Biol; 2022; 368():213-259. PubMed ID: 35636928 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages. Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876 [TBL] [Abstract][Full Text] [Related]
38. Macrophage heterogeneity in atherosclerosis: A matter of context. Wieland EB; Kempen LJ; Donners MM; Biessen EA; Goossens P Eur J Immunol; 2024 Jan; 54(1):e2350464. PubMed ID: 37943053 [TBL] [Abstract][Full Text] [Related]
39. Latitudinal and longitudinal regulation of tissue macrophages in inflammatory diseases. He X; Tan S; Shao Z; Wang X Genes Dis; 2022 Sep; 9(5):1194-1207. PubMed ID: 35873033 [TBL] [Abstract][Full Text] [Related]